Donaco International Ltd is engaged in the operation of leisure and entertainment businesses. It is organized into three segments: Casino Operations - Vietnam, Casino Operations - Cambodia, and Corporate Operations. The company generates maximum revenue from the Casino Operations - Vietnam segment. The company operates in Vietnam, Cambodia and Australia.
相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- The US Treasury is drafting rules that would likely let American drugmakers keep striking most licensing deals for Chinese-developed medicines. - The rules would permit investment in Chinese drug programs unless they involve pathogens or weaponizable biotechnology, sources briefed on the process said. - Pfizer and other large drugmakers have lobbied against broad restrictions, while smaller biotechs and some lawmakers want tighter curbs on China deals.
- Waterfall Scientific will lead a six-company consortium under ARPA-H's GIVE program, supported by up to $54.5 million in funding. - The ESCALATOR project aims to build an end-to-end, continuous-flow platform for rapid, on-demand production of high-purity mRNA therapeutics and vaccines. - The platform seeks to shorten mRNA manufacturing lead times from weeks to days and reduce costs and footprint. - Consortium partners include Ansa Biotechnologies, Volta Labs, Polymorphic Biosciences, Tensentric, and Ginkgo Bioworks.
- Transfyr, a Cambridge, Mass.-based startup, launched with $25 million in seed funding led by General Catalyst to build a physical AI platform for real-world science. - The platform captures hands-on bench science and converts it into machine-readable data to enable closed-loop AI and automation systems. - Founded by Anna Marie Wagner (former Ginkgo Bioworks executive) and Dr. Renee Wegrzyn (founding ARPA-H director), the company aims to solve technology-transfer bottlenecks in drug development. - Transfyr cites an Accenture report estimating that 64% of drug-launch delays in 2024 stemmed from chemistry, manufacturing, and control (CMC) issues, including tech transfer.
- The global synthetic biology and biomanufacturing market is projected to grow through 2037 across healthcare, chemicals, food, agriculture, and sustainable materials, with a new report profiling 327 companies. - Scale-up remains the industry's binding constraint, as the transition from bench to commercial fermentation volumes exposes oxygen transfer, heat removal, contamination, and downstream recovery problems that destroy process economics. - Three structural shifts define the current period: convergence of synthetic biology with industrial enzymes and white biotechnology, elevation of policy to a primary determinant, and a bifurcating market favoring companies with production assets. - The design-build-test-learn cycle, powered by AI and computational biology, has compressed enzyme development from years to weeks, with machine learning-guided strain development showing 1.8-fold improvement over standard methods.
- Microsoft Discovery, a cloud-based agentic AI platform for scientific research, entered general availability at Build 2026 after a one-year private preview. - The platform deploys specialized AI agents that coordinate data analysis, hypothesis generation, experimentation, and knowledge management across the full iterative scientific process. - Early adopters including Yale Engineering, PNNL, Ginkgo Bioworks, and GSK have applied Discovery to battery materials, biosystems engineering, biological discovery, and drug development workflows. - Microsoft's Majorana 2 quantum chip development used Discovery to cut the expected overall chip development timeline in half, demonstrating real-world acceleration of complex R&D.
- Imperagen secured £5 million in seed funding led by PXN Ventures to expand its quantum physics and AI-driven enzyme engineering platform, bringing total capital raised to £8.5 million. - The company's technology combines quantum-based simulations with AI models and automated robotics to predict and optimize enzyme mutations, moving beyond traditional trial-and-error methods. - Commercial applications have demonstrated significant productivity gains, with enzyme improvements of 677 times and 572 times achieved after five optimization cycles in partnership with a Fortune 500 personal care company. - The funding will support R&D expansion, laboratory scaling, AI team growth, and commercial development across pharmaceuticals, life sciences, personal care, and industrial biotechnology sectors over the next 18 months.
- ProQR Therapeutics announced a strategic partnership with Ginkgo Bioworks to leverage autonomous laboratory technology for high-throughput data generation supporting AI-enabled drug discovery for its Axiomer RNA editing platform. - The company established an AI Advisory Board comprising industry leaders from organizations including NVIDIA, Owkin, and Hugging Face to guide the development of AI strategies for optimizing Axiomer editing oligonucleotides. - ProQR expects to advance its first AI-discovered development candidate into clinical trials with a CTA filing anticipated in mid-2026 and initial clinical data expected by year-end 2026. - The partnership provides access to Ginkgo's 50+ instrument autonomous lab called Nebula, which is designed to remove bottlenecks in AI-enabled drug discovery by increasing experimental data generation speed and scale.
- ProteoNic BV has licensed its proprietary 2G UNic® vector and transposon technology to Ginkgo Bioworks for a $22.2 million BARDA-funded project aimed at developing cost-effective monoclonal antibody manufacturing for anti-filovirus therapies. - The project brings together a consortium including Advanced BioScience Laboratories, Isolere Bio, NeuImmune, and ProteoNic to create rapid, scalable biomanufacturing solutions for critical medical countermeasures against Ebola and Sudan Virus infections. - ProteoNic's 2G UNic technology is designed to maximize expression and productivity in mammalian systems, potentially enhancing manufacturing efficiency and yield while reducing time and costs for large-scale bioproduction. - The collaboration represents a strategic expansion for ProteoNic into next-generation biologics manufacturing and supports strengthening domestic biomanufacturing resilience against future global health threats.
- STRM.BIO received up to $8.4 million in first-phase funding from ARPA-H to develop its proprietary megakaryocyte-derived extracellular vesicle platform for in vivo immune cell engineering. - The company's novel cell-derived delivery system aims to overcome key barriers limiting current viral and synthetic in vivo delivery technologies for gene therapy applications. - STRM.BIO will lead a collaborative effort with Ginkgo Bioworks, University of British Columbia, and Advanced Bioprocess Services to develop in vivo CAR-T therapeutics using non-viral delivery methods. - The platform enables precise delivery of complex genetic cargos directly to bone marrow with potential for multiple dosing applications.
- Ginkgo Bioworks has partnered with STRM.BIO and the University of British Columbia under ARPA-H's EMBODY program to develop in vivo CAR therapies for autoimmune diseases like systemic lupus erythematosus and myasthenia gravis. - The INVITE-ME project combines STRM.BIO's megakaryocyte-derived extracellular vesicle delivery system with Ginkgo's RNA construct design expertise to engineer T cells directly in bone marrow without costly ex vivo manipulation. - The collaboration aims to create transformative therapies that can selectively eliminate autoreactive B and T cells, potentially offering durable treatments while avoiding the broad immune suppression risks of current therapies.
